CytoSorbents Corporation, traded on Nasdaq under the ticker CTSO, has reported its Q2 2025 financial results, showcasing a revenue of $9.6 million. This marks a 9% increase compared to $8.8 million in the same period last year, or a 4% rise on a constant currency basis. The growth was largely driven by a 22% year-over-year increase in Germany, following a proactive reorganization initiated in Q1, as well as robust performance in other direct EU territories. The company's distributor sales were among the best ever, only surpassed by a record Q2 2024. Product gross margin remained steady at approximately 71%, consistent with the average margin from 2024. Despite these strong sales figures, CytoSorbents reported an adjusted EBITDA loss of $2.6 million, compared to a $2.2 million loss a year ago. CytoSorbents continues to drive its core business toward achieving cash flow breakeven by the end of 2025, supported by a strong balance sheet with $11.7 million in cash, cash equivalents, and restricted cash as of June 30, 2025. The company also received $1.7 million from the sale of NOL and R&D credits in April and has a $5.0 million second tranche available at its option under its debt agreement.